Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis
Key Highlights
- ➤MitoCareX adds an expert bioinformatician to expand disease-pathway analysis
- ➤Nexentis plans to integrate disease-biology insights into its drug-discovery platform
- ➤Developing capabilities aim to improve target assessment before resource-intensive discovery activities
- ➤MitoCareX’s platform combines disease biology with structural modeling and computational chemistry
Expert Statements
David Palach, Chief Executive Officer of Nexentis Technologies Inc.
“Expanding our internal bioinformatics expertise represents a deliberate step in broadening the scientific foundation of MitoCareX’s computational drug-discovery platform.”
David Palach, Chief Executive Officer of Nexentis Technologies Inc.
“Our established capabilities enable us to examine protein structures and potential molecular interactions.”
David Palach, Chief Executive Officer of Nexentis Technologies Inc.
“The broader bioinformatics capabilities now being developed are intended to add another important perspective by placing potential targets within the context of disease-relevant biological pathways.”
David Palach, Chief Executive Officer of Nexentis Technologies Inc.
“We believe that bringing disease-biology insights together with structural and molecular analysis may strengthen the basis on which future discovery opportunities are evaluated and prioritized.”
MitoCareX expands its internal bioinformatics expertise to broaden the analysis of disease biology within its computational drug-discovery activities
Ness Ziona, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that MitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary, is broadening its existing bioinformatics capabilities to include a greater focus on the analysis of disease-relevant biological pathways within its computational drug-discovery platform.
Get started
Create a free account to read the full story.